Globally, there are more than 650,000 newly diagnosed cases of bladder cancer annually, with up to approximately 80% of these ...

Discover how urinary microRNA biomarkers can non-invasively identify aggressive bladder cancer subtypes. Read more on this ...

The poster presentation will include updated safety and efficacy data from approximately 25 six-month evaluable BCG-Unresponsive NMIBC patients in the ongoing Phase 2 ADVANCED-2 trial. ADVANCED-2 ...

IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.

Shares in ImmunityBio rose sharply after the company said it has agreed a path with the FDA that will allow it to refile for ...

In a significant development for the field of oncology, ImmunityBio, Inc. (NASDAQ: IBRX) has recently announced positive results from its clinical trials focused on treating bladder cancer. This ...

ImmunityBio shares jumped in premarket trading after the FDA outlined next steps for expanding ANKTIVA’s bladder cancer label ...

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its ...

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA ...

Detailed price information for Biovaxys Technology Corp (BVAXF) from The Globe and Mail including charting and trades.

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc.

Ferring Pharmaceuticals and Theralase® Technologies Inc. are pleased to announce that they have entered into a collaborative clinical development agreement ("Agreement") on January 9, 2026. The ...